Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.3.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KN.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.61NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.37NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XASNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.3.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BE.1.4.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CH.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.53NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBLNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EK.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.466.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.36NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.222NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.470NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.31 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.51 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.122.5 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.40.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.13.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.10.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GS.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HG.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.323NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FU.1.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FN.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.74NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.53NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JB.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDK.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.58NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.1.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GA.10.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CP.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.39NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.3.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BM.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.57NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EF.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used